Resources

This section covers crucial information about cancer, links to recogized information sources and frequently asked questions by our patients rearding Mistletoe therapy. We will be more than happy to answer additional questions and replenish this information bank for you time-to-time. Please write to us at info@cancercure.org.in

Frequently Asked Questions

Why cancer treatment should begin immediately after diagnosis?

Cancer is serious disease, and if not treated can lead to death in a small period of time. Additional problems are caused if it becomes metastatic and hastens death. Standard therapy against cancer is normal in this cases, and also additional treatments, like miseltoe should be provided for improving the expectation and results. The producer recommends beginning of the therapy as soon as possible.

What is MISTLETOE?

Mistletoe is a herbal medicinal product, consisting strictly of active ingredients from herbal origin. The action of mistletoe is primarily anti-cancer. It improves general condition of the body.

What is the proof that MISTLETOE works?

The best results are obtained when miseltoe is used on soft tissues (e.g. lung cancer, prostate cancer, breast cancer and digestive organs cancer), but we have documented cases of total healing of all types of cancer.

Which types of cancer can be treated with MISTLETOE?

There have been many clinical trials according standard protocol which have shown the benifits and survival rates and anti-metastatic properties of mistletoe.

Can I use MISTLETOE during chemotherapy or radiotherapy?

Yes. There is no point of interaction between these therapies. Only better and improved results can be expected.

In which other conditions, except cancer, can I use MISTLETOE?

When the organism is exhausted (due to different etiology), for improving resistance of organism, as adjuvant in standard therapy of some acute and chronic diseases, anemia, multiple sclerosis, alterations in immunity and bad general condition.

How long will treatment take?

The first results of cancer suppression can be expected after 4 weeks of use of MISTLETOE. If there is an improvement of patients' general state, or improvement of blood tests, treatment should continue up to six months. After this treatment it is not necessary, but is desirable to take 1-2 doses yearly. to avoid reccurence it is advisable to take it for a longer duration depending on the case.

What is the proof that MISTLETOE works?

The best results are obtained when miseltoe is used on soft tissues (e.g. lung cancer, prostate cancer, breast cancer and digestive organs cancer), but we have documented cases of total healing of all types of cancer.

Is there a special diet proposed for use during treatment?

There is a special diet, but it is not because of using MISTLETOE, but because of the health condition of the patient. The patient must stop eating food that is feeding the cancer cells. This diet includes a lot of vegetables and fruits (except bananas), and excludes fats, red meat and sugar.

Useful Information

What is the history of the discovery and use of MISTLETOE as a complementary or alternative treatment for cancer?

The first results of cancer suppression can be expected after 4 weeks of use of MISTLETOE. If there is an improvement of patients' general state, or improvement of blood tests, treatment should continue up to six months. After this treatment it is not necessary, but is desirable to take 1-2 doses yearly. to avoid reccurence it is advisable to take it for a longer duration depending on the case.

What is the theory behind the claim that MISTLETOE is useful in treating cancer?

MISTLETOE extract is studied as a possible anticancer agent because it has been shown to:
- Have effects on the immune system.
- Kill mouse, rat, and human cancer cells in the laboratory.
- Protect the DNA in white blood cells in the laboratory, including cells that have been exposed to DNA-damaging chemotherapy drugs.

How is MISTLETOE administered?

MISTLETOE extracts are usually given by injection under the skin (subcutaneous). Less common ways to give MISTLETOE include by mouth(oral suspension), into a vein (intravenous or IV), into the pleural cavity, or into the tumor. In most reported studies, injections under the skin were given 2 to 3 times a week for various lengths of time.

What preclinical (laboratory or animal) studies have been conducted using MISTLETOE?

Many laboratory and animal studies have been done with MISTLETOE, either alone or combined with other agents. Laboratory studies have suggested that MISTLETOE may support the immune system by increasing the number and activity of various types of white blood cells. One type of European MISTLETOE (AbnobaQ) used in a 2004 laboratory study showed a strong anticancer effect on certain types of cancer cells but no anticancer effect on other types of cancer cells. While one laboratory study reported that MISTLETOE extract caused several types of human cancer cells to grow faster, this was not found in other recent lab studies. Studies testing MISTLETOE's ability to stop cancer cell growth in animals have yielded mixed and inconsistent results, depending on the extract used, the dose tested, the way it was given, and the type of cancer studied. Results of a few animal studies have suggested that MISTLETOE may be useful in decreasing the side effects of standard anticancer therapy, such as chemotherapy and radiation therapy, and that it counteracts the effects of drugs used to suppress the immune system, such as cortisone.

Have any clinical trials been conducted using MISTLETOE?

Most clinical trials using MISTLETOE to treat cancer have been done in Europe. Most study results have been published in German. Although many of these trials have reported MISTLETOE to be effective, there are major weaknesses in almost all that raise doubts about their findings. Weaknesses have included small numbers of patients, incomplete patient data, lack of information about MISTLETOE dose, and problems with study design. Many studies involve using MISTLETOE as adjuvant therapy in patients with cancer. One retrospective cohort study done between 1993 and 2000 looked at the use of a MISTLETOE extract (Abnoba) as long-term adjuvant therapy in 800 patients treated with chemotherapy and/or radiation therapy for colorectal cancer that had not spread. The study found that patients treated with Abnoba had fewer adverse events, better symptom relief, and improved disease-free survival compared to patients who did not receive Abnoba as adjuvant therapy. In 2002, the National Center for Complementary and Alternative Medicine (NCCAM), in cooperation with the National Cancer Institute (NCI), began enrolling patients for a phase I clinical trial of a MISTLETOE extract (Helixor A) and gemcitabine in patients with advancedsolid tumors. This combination showed low toxicity and showed treatment benefits in almost half the patients. The trial is now closed and the data are being analyzed.

Have any side effects or risks been reported from MISTLETOE?

Very few serious side effects have been reported from the use of MISTLETOE extract products. Common side effects include soreness and inflammation at injection sites, headache, fever, and chills. A few cases of severe allergic reactions, including anaphylactic shock, have been reported.

Important Tip

At this time, there is not enough evidence to recommend the use of MILSTLETOE as a treatment for cancer except in carefully designed clinical trials. These trials will give more information about whether MISTLETOE can be useful in treating certain types of cancer.